BioSelective Capital’s CDMO acquisition reshapes domestic pharma manufacturing landscape

Forma Life Sciences launches from BioDuro’s CDMO assets. See how this reshoring move changes U.S. oral formulation outsourcing and CDMO competition in 2026.

Forma Life Sciences launches from BioDuro’s CDMO assets. See how this reshoring move changes U.S. oral formulation outsourcing and CDMO competition in 2026.